PHARMA HEAVYWEIGHTS ZYDUS LIFE AND TORRENT PHARMA TEAM UP TO SELL SEMAGLUTIDE IN INDIA

and have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market. Under the agreement, will manufacture the product while will take care of marketing it in India under its own brand name Sembolic. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. It is also indicated for chronic weight management in adults. This collaboration is set to benefit both the companies in terms of sales and profitability. While the stock price of has gained over 30% in the last one year, the stock price of has been consolidating at the same price level with no relevant gain. However, is trading at a much attractive P/E of 17.4 as compared to the P/E of which is currently 62.1. Hence both companies are attractive options for momentum investing and value buying.